These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32901994)

  • 21. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
    Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview.
    Verghese NR; Barrenetxea J; Bhargava Y; Agrawal S; Finkelstein EA
    J Mark Access Health Policy; 2019; 7(1):1601060. PubMed ID: 31007877
    [No Abstract]   [Full Text] [Related]  

  • 27. Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States.
    Rodwin MA
    Int J Health Serv; 2021 Jul; 51(3):379-391. PubMed ID: 33686883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
    Chen Y; Schweitzer SO
    Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study.
    Armeni P; Jommi C; Otto M
    Eur J Health Econ; 2016 Nov; 17(8):963-977. PubMed ID: 26507643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of insurance policies in the drug pricing landscape.
    Savova A; Manova M; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):189-202. PubMed ID: 38064353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: analysis of the Belgian national database.
    van Driel ML; Vander Stichele R; Elseviers M; De Sutter A; De Maeseneer J; Christiaens T
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1113-22. PubMed ID: 18823069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
    Antoñanzas F
    Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New developments in pricing and drug reimbursement in France.
    Pelc A; Castan JP
    Pharmacoeconomics; 1994; 6 Suppl 1():28-35. PubMed ID: 10155583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
    Kang SO; Kim SJ; Park S; Jang SI; Park EC
    Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Policy in Slovakia.
    Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
    Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.